GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Bell reported relationships with the Dementia Australia Research Foundation, GlaxoSmithKline Supported Studies Programme ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...